What Absci Corp does.

We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop. We focus on underexplored mechanisms where unmet medical need is high and competition is low.

We have advanced our first two programs from AI design to IND (or foreign equivalent) in around two years with a total investment of approximately $15 million per program, compared to an industry average of 4–6 years at a cost of greater than $50 million. This combination of underexplored target selection and capital-efficient execution is central to our strategy.

Our lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval. We believe PRLR is an underexplored target with the potential to provide durable, disease-modifying effects. If successfully developed, ABS-201 could establish a new treatment category in indications where current options remain inadequate. ABS-201 is being developed for two indications, androgenetic alopecia (AGA) or pattern hair loss (PHL) and endometriosis, each with large affected populations and significant unmet need:

Revenue and profit, by fiscal year.

More on ABSI.

• Absci Corp summary
• Absci Corp financial statements
• Absci Corp key metrics
• Absci Corp health scores and style box
• Absci Corp earnings
• Absci Corp dividends
• Absci Corp valuation
• Absci Corp ownership and insiders
• Absci Corp peers

Figures from Absci Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.